- NewsCategory：
- All Company news Industry news
common105One result
-
1017
WindMIL Therapeutics and University of Californi$↓↓∞a, Irvine Announce Collaboration to <♥✔☆Collect Bone Marrow from Patie≥π↕nts with Gliomas
WindMIL Therapeutics and University of Calif ☆">ornia, Irvine Announce Collab↑λoration to Collect Bone Ma÷<β≥rrow from Patients with GliomasWEDNESDAY, OC≠♣TOBER 16, 2019WindMIL Therapδ¶≤πeutics and the University ofλ★ California, Irvine (UCI) today announced that t✘Ω"he first patients have been identified in an εinvestigator-sponsored study f★εβor the collection of bone marrφ σow from patients with gliomas. The study wil€γπl evaluate generating '₩marrow infiltrating lymphoc§≠γφytes (MILs™) for these patient••↔↕s through WindMIL’s proprietary cellular act ←ivation and expansion process. The study is bei♦וng conducted at UCI.“Patients suf♥©₽∑fering with glioblastomaε>ε are in great need of new, promising t≥ ★reatments that might adva₹∑$↔nce the current standard of care,” s<aid Daniela A. Bota, MD✘, PhD, director of t ♣he UCI Health Comprehensi↑±εve Brain Tumor Program, senior associa₩→☆ te dean for clinical research, UCI School₩&↑ of Medicine and clini←♥cal director, UCI Sue & Bill Gross Stemφ'™ Cell Research Center. “The Unive∏≤rsity of California,₹∑ Irvine is excited to play ₩≥a key role in research that may le♣←ad to a clinical trial that enlists the immune σ∑system in novel ways to fight thi✔→♣∞s terrible disease.”Gliomas are the mos≤δ↓∑t common of the malignant br∏™ain tumors. Glioblastoma, the most common glioεσ¶ma, has a five-year survival of →®∏less than 5 percent. Additional tr£≈≈eatment options are urgently needed for∑♥ these patients. Adoptive imm★>←γunotherapy is a possible approach forγ♣ gliomas and the use of MILs≠₩, a cell therapy that is naturall₽>y tumor-specific, is one such t≤₹reatment option.The bo←< <ne marrow is a unique niche i¥₩♥n the immune system to which antigen-'∑experienced memory T cells traffic and a✔§re then maintained. WindMIL has✘ developed a proprieta ry process to select, ac☆÷₩↓tivate and expand these memory T ce♥α>βlls into MILs. Because memory T cells ♠©'in bone marrow occur as a result☆φ£ of the immune system’s recog£♦✘nition of tumor antigens, MILs are specif☆>σ©ically suited for adoptive cellular i£♠∏mmunotherapy and are able to directly eradicate$←♥ or facilitate eradi≤☆cation of each patient’s unπ↕ique cancer. WindMIL is currently $$∑∏studying MILs in multi↓↑ple myeloma, non-smalλ&l cell lung cancer and squamous cell carcinoma ✘≥γof the head and neck, anλ↑→ d plans to expand into other so Ωlid tumors.“WindMIL is≤☆ looking forward to working with theλφε University of California, Irvine on this exc♦iting project and is optimisti& c that MILs may offer the potential to help patieβ×nts with these hard-to-treat diseases,”↕$α' said Monil Shah, PharmD,✔• MBA, Chief Development Officer at Wi∞$ndMIL.information source:pharma<δ→ focus AsiaThe original link:https://www≥↑.pharmafocusasia.com/news/wind•♣✔mil-therapeutics-and'₹✔-university-of-california-irvine-announce-collabo≥♥♦♥ration-to-collect-bon>α¥e-marrow-from-patients-with-glioma¶→s2019 Asia-pacific pharma IP Leader Summit: http✔§://en.zenseegroup.com/p/510934/∏♠×₽will be held in Beijing on Nεδovember 14-15, and will attract more than Ω<γ500 industry experts from domestic and foreign ph↑✘armaceutical companies, biotechnology <₽Ω<companies, governments, associations, l ★aw firms, intellectual property ag↕£ents and other companies to attend.Official ™•registration and consultation channel∏♦φs:Contact：AnnPhone: 021-65650305Email：Marketing@z$≠enseegroup.comhttp://en.zenseegrou•≠€p.com/p/510934/ -
1016
CRISPR Therapeutics and KSQ Thγ★λerapeutics Announce License $←"Agreement to Advance☆← Companies’ Respective Cell Therapy Programs®$↑ in Oncology
CRISPR Therapeutics a∞β•↔nd KSQ Therapeutics Announce License Agre&σ£™ement to Advance Companies’ Respect↕×↔γive Cell Therapy Programs in ≤↕OncologyWEDNESDAY, OCTOBER 16, 2019CRISPR Therap×eutics, a biopharmaceutical company £☆ &focused on creating transformative gen$∑e-based medicines for ser→←ious diseases, and KεαSQ Therapeutics, a biotechnology company using ☆£CRISPR technology to enable the company’s powe&₩≠rful drug discovery engine to $±β™achieve higher probabilities of success in d'←¥rug development, today announced a ₽™license agreement whereby CR™α ISPR Therapeutics will gain access to KSQ intel¶≥₹lectual property (IP) for editing certain novel♦&> gene targets in its allogeneic oncology cell φ therapy programs, and KSQ will gain access to CΩδ✘RISPR Therapeutics’ IP for editing novel gene targets ident₩$εified by KSQ as part of its current and fut₩ ure eTILTM (engineered tumor ∞♣infiltrating lymphocyte) cell programs. The"πλφ financial terms of the agreemδ€ent are not being disclosed.÷≈₽“We are thrilled to gain access to CRISPR > Therapeutics’ foundational IP estate thr♦¶ough this agreement,” said David Meeker, M.D., Ch∑ ★ief Executive Officer at KSQ Therapeutiα"cs. “Our eTILTM programs involve editing gene tar"α©↕gets in human TILs that were d•₽<™iscovered at KSQ by applying our proprietary CRI↔SPRomics® approach to immune cells in mu©®Ωδltiple in vivo models. This agreement clear' s an important path for us to be able t₹™↑o bring these programs thr≠↓ough development and commercia§≥lization, leveraging CRISPR Therapeutics’<∑§Ω proprietary editing technology.”The ge✘ ne targets within the scope of the license agree→♠₽ment were identified using ×→KSQ’s proprietary CRISPRomics® drug discovery e↕₽λngine, which allows genome-s★✔σcale, in vivo validated, unbiased drug ↔φdiscovery. These specific targets we&γ re uncovered in screens to identif≥♠y genetic edits that could enhance the func₽≈tionality and qualit↔ y of adoptive cell therapies in oncolo₩ "&gy.“KSQ has built an industry-leγading platform to screen for novel gene targets × ★using its technology, and has identified a ≥₽group of targets that could help u♣₹£≥nlock the full potential of adoptive cell thera£πpy in oncology,” said Samarth K ∏>ulkarni, Ph.D., Chief Executive ←≈Officer at CRISPR Therapeutics. ≤♣δ“As a result of this license≠≥™ agreement, CRISPR Therapeutics will haveγδε the opportunity to bring these novel targets in✔≤to our leading allogenΩ÷eic CAR-T development platform←✔ to further strengthen ou> ∑r future programs in th♥✔ ©is important therapeutic area.”informa₩★tion source:pharma foc±✘us AsiaThe original link:https:https://www.pharm≠ βafocusasia.com/news/crispr-therapeutics-and-ksq-t£↓herapeutics-announce-license-agree♣§→ment-to-advance-companies-resp©≤₹→ective-cell-therapy-programs-in-✘γ★ oncology2019 Asia-pacific pharma →₹☆IP Leader Summit: http://en.zense>★&egroup.com/p/510934/ will be held in&n∏λ÷bsp;Beijing on&nbsπ§≠p;November 14-15, and will attra®¶ct more than 500 industry experts fro≈m domestic and foreigγ¥÷n pharmaceutical companies, biotech">©nology companies, governments, ass≠∏×ociations, law firms, intellectual property>π agents and other companies to attend.Offici×≠♠εal registration and consultation channels:↑ Contact：AnnPhone: 021-65650305Ema✔•¶♦il：Marketing@zenseegroup.comhttp://±&en.zenseegroup.com/p/₩510934/ -
1015
Shionogi enters into a new license agreement and ←Ω≤research collaboration for ≥←★the treatment of mycobacterial diseases withα≈& Hsiri Therapeutics, Inc.
Shionogi enters into a new license ag→£reement and research collabora☆≥✔tion for the treatmen↔∑¶•t of mycobacterial diseases with Hsiriε• Therapeutics, Inc.MO←↑βNDAY, OCTOBER 14, 2019Shionogi & C←÷✔o., Ltd. today announced that§≥β it has entered into↔↔ a new license agreement with Hsiri Therape≠≈ε♣utics, Inc. (Head Office: Media, ₽♠$PA, USA; President and CEO: William Claypool, M.D♥♥♦↑.; hereafter "Hsiri") regarding a collabo$"rative research and development program to discov ≥>×er and develop additiona★®★£l novel therapeutics foσ™♣r non-tuberculous mycobacterial (NTM) di✔÷£seases and tuberculosis (TB∏γ). This new collabora↑♣'£tion will include technology that complemδ ☆ents Shionogi's earlier collaboration arrangement≈φ with Hsiri.The new technology tφ¥¶o be licensed from Hsiri has a novel mechanis> ±εm of action, will be complementary t♣¥÷o Shionogi's current research with Hsiri,• and is anticipated to b&₩→"e more effective than current therapies for mδ♥♥ycobacterial infections. Shionogi's strength in σ∑γsmall molecule drug discovery a✔♣★φnd development in the antibacterial area will s×₹¥✘upport development of Hsiri's inn≠™ovative therapeutics in th∏←±βis collaborative progra♠m. Under the terms of this π∏agreement, Shionogi will have exclusive worlλβdwide rights to develop, manu$facture, and commercialize ©÷•↕the compounds generated from the cασΩollaboration. Hsiri will receive an upfro ♣↓nt license fee, potential development miles&→∏εtones, and royalty payme∑ ®γnts based on sales from Shionogi.It is reported φ★that the number of patients suffe≤♥∞ring from NTM diseases has been ®&∑increasing, especially in devΩ♣✘σeloped countries, in recent year×±$s. There is a medical need to develop $$novel anti-NTM drugs beβ∞cause of the long duration of treatment an<π₽d insufficient treatment outcome of cur€®£rent therapeutics. TB is one →<× of the three major i€$nfectious diseases in the wo₩←σ•rld, and new cases of TB a re estimated to be 10.4 millionπε☆/year. Multidrug-resi £©stant TB (MDR-TB) and extensively dr®₽ug-resistant TB (XDR-TB) have become a major publΩ®ic health concern, and novel drugs ± ÷γfor MDR-TB and XDR-TB are anticipated.∏÷Shionogi's research and devΩ""elopment targets infectious disease ↔ as one of its priority area>©☆ s, and Shionogi have positioned "protecti φπng people from the threat of i♣ε€nfectious diseases" as one of its social mission¥> targets. Through this coope♣ε™±ration, Shionogi strives constantly to br>★ing forth innovative drugs for the treatment φ of infectious diseases, to prφ≈<otect the health of patients we serve.info€&δ↔rmation source:pharma focus AsiaThe origin✘al link:https:https:https://www.pharmafoc♣Ω→usasia.com/news/shionogi-enters-into-a-new-licens'$e-agreement-and-research-collaboration-for-t<αhe-treatment-of-myco§α→bacterial-diseases-with-hsirו→i-therapeutics-inc201φ ® 9 Asia-pacific pharma IP Leadδ$£Ωer Summit: http://en.zenseegrφ ₩oup.com/p/510934/ will be held α' in Beijing on Novem"δ₽ber 14-15, and will attract more than 500 industr'λy experts from domestic and<✔ foreign pharmaceutical co÷ ♣mpanies, biotechnology companies, governments, a§∏✔ssociations, law firms, intellec♦δ☆★tual property agents and other companies t®÷"÷o attend.Official registration and consultatioδ©n channels:Contact：Ann♦σPhone: 021-65650305Email：Marketing@zenseegroup.c$™λomhttp://en.zenseegroup.com/p/5109™π←34/ -
1014
Advaxis and UCLA Enter Collaboration for Gliob €lastoma Immunotherapy Discovery Research
Advaxis and UCLA Enter Collabo™¶₽§ration for Glioblastoma↔ Ω Immunotherapy Discovery ResearchFRIDA ←Y, OCTOBER 11, 2019Ad£↔↑vaxis, Inc., a clinical-₽ε$stage biotechnology company focused on the di¥scovery, development and commercializatiΩ♣ δon of immunotherapy prodπ™¶&ucts, today announced a re§•≤search collaboration agreement with t≈₽βhe University of California Los Angeβ☆₽£les (UCLA) to conduct preclinical studies evaΩπ luating the Company’s Lm technology in mouse tumo♦↔✔r models of glioblastoma multifor£↓ me (GBM). Specifically, the collabo★∑ration with Dr. Vaithi Arumugaswam¥βi’s group at UCLA’s Department of Molecul ♠ar and Medical Pharmacology will iγ$♣∑nvestigate anti-tumor immunit&φy and anti-tumor responses generated b≤↓y Lm vaccines that expre™εss diverse glioblastoma neoantigen'σs.“We are excited that Dr. Aru✘βmugaswami and his colleag'£ues at UCLA will investigate the potential↕₩₹ of our Lm technology platform in GBM,"↕↔• one of the deadliest cancers,” γ↑ ←said Andres Gutierrez, Executive Vice Pre←β÷sident and Chief Medical Officer ↓of Advaxis. “Contrary to other tum₽ ₹or types, GBM has not see↓©n much success in tar™≤geting by immunotherapeutic agen©σts due to a low tumor mutation burden, high tu♠→≥mor heterogeneity and presence of the bl≠≥ood brain barrier, among other fac™×tors. Hence, Dr. Arumugasw§™↑÷ami’s characterization of th$ ↓∏e neoantigen landscape and immune res×'•ponses to Lm- constructs may lead to th↑₹∞e development of novel therapies with cli"γ®✘nical activity in this elusive cancer.”♦π☆information source:≥£±pharma focus AsiaThe original link:htt✔¥↕ps:https:https://www.pharmafocusasia.com/news/ad®↑>÷vaxis-and-ucla-enter-collabo✘≠"↔ration-for-glioblast'★oma-immunotherapy-discovery-re€↔ search2019 Asia-pacific pharma IP Leader Summ±∑☆it: http://en.zenseegroup.com/p/510934/w ε®≈ill be held in Beijin✘®g on November 14-15, aφ•¥nd will attract more than 500 industry experts frש ≤om domestic and foreig≤n pharmaceutical compan↔±®ies, biotechnology companies"™ε₽, governments, associations, law firms, int£∑ellectual property agents and oth₩♣✘er companies to attend.Official regi€stration and consultation channels:Contact：AnnP€€hone: 021-65650305Email：Marketi↓α≈ng@zenseegroup.comhttp://en.zenseegroup.com/p/510≥←λσ934/ -
1011
Viela Bio Enters Strategic Colla π'≥boration with Mitsubishi Tanabe Pharma to D↕ evelop and Commercialize Inebil₹¥•izumab for Autoimmune Dis£γeases in Japan and Other Asia Regions
THURSDAY, OCTOBER 10, 20"→£←19Viela Bio, Inc. and Mitsubishi Tanabe Pharma ←™¥Corporation (“MTPC”) today announcγ₩>®ed a collaboration focus≥Ω♠₩ed on the development and commerci±∏alization of inebilizumab←ε∏ – Viela’s humanized anti-CD19 monoclona•l antibody – in nine Asiα♠a regions for neuromyelitis optica spectrum d'™isorder (NMOSD), as well as other potential fuγ↑♣§ture indications.“This∑ ✔ partnership adds to our abili≠♠&ty to commercialize inebilizumab globally,&£δπ subject to regulatory approval,” commented ✔☆Bing Yao, Ph.D., Viela’s Executiv↕↔✔e Chairman and Chief Executive Officeα♠r. “As a well-established ≤φpharmaceutical compa™"πny in Japan, Mitsubishi Tanabe has stε♠© rong product developm§'★¶ent and commercialization capabilities in ¶≠Asia, and we believe, is an ideal partner €©for expanding inebilizumab’s potential reach to t "housands of additional patients in n≈≤γ¥eed of viable treatments, with NMOSD as ₽ an initial indication.”Under terms of th∏÷π≈e collaboration, Viela will receiλλve an up-front licensing fee of $3¥£♠0 million as well as additional payments contingα∏÷≤ent on certain development and commercial mile≈∑ stones, plus payments based, in γ$♥part, on sales revenue. MTPC will be responsibleφ♠β≥ for leading development and commerci©×alization of inebiliz§¶÷₩umab in Japan, Thailand, South Korea, Indoββγ§nesia, Vietnam, Mala♥ ysia, Philippines, Singapore₽∏, and Taiwan.“Our org&₩anization is delighted to partner wi& th Viela to develop and£' commercialize their promising producε₽'t candidate inebilizumab for autoimmune and infl×>ammatory diseases,” said Masayuki Mits ↔uka, MTPC President & Representative Dirδ$≈ector. “Inebilizumab is an exciting prod ★βγuct candidate that, based on the resul₩∞ts from the N-MOmentum pivotal stud↕₹'y, is well-positioned to provide φ meaningful benefit for §<patients with NMOSD, and potentially ✘↑© additional diseases, subject to π≤↕ regulatory approval. We are exc>↔÷ited to work with Viela to advance inebilizumab✘≥&∑ in Japan and other Asia regions, and look f££∞orward to a productive partnershi₩∏p between our companies.”The U.S. Food an€♥d Drug Administration (FDA) recently₹©← accepted for review Viela’s Biologics Lice↕✔nse Application (BLA) ¶¶γ for inebilizumab for the≈∞ treatment of NMOSD. γ;information source:pharma focus AsiaThe o↕®©riginal link:https:https://www.pha 'rmafocusasia.com/news/v≥↑π☆iela-bio-enters-strategic-™βcollaboration-with-mitsubishi-ta£ nabe-pharma-to-develop-and-commeαλλrcialize-inebilizumab-for®∑•-autoimmune-diseases-in"←-japan-and-other-asia-regions20α'>&19 Asia-pacific pharma IP Leader Summit×∑¥: http://en.zenseegroup.com/p/510934/will b∑♥e held in Beijing &n•$★bsp;on November 14-15, and will att×÷ract more than 500 industry ₽"→experts from domestic and foreign pharmaceut€≥ical companies, biotechnology α$ companies, governments, associ✘<§ations, law firms, intellectual p♥✔™ roperty agents and other companies to aλ§☆₹ttend.Official registration and cλ®onsultation channels:Contact：AnnPhone: 02÷φ1-65650305Email：Marketing@zenseegroup.comh÷↕ttp://en.zenseegroup.com/p↑ ☆/510934/
Contact Us
Zensee_Daystar online
© 2011-2016